Collegium 2025 Q3 Earnings 237.5% Net Income Growth and Guidance Raise

Collegium (COLL) delivered a strong Q3 2025 performance, exceeding revenue and earnings expectations while raising full-year guidance. The stock surged 21.77% month-to-date and 14.05% weekly, reflecting investor confidence in its growth trajectory.

Revenue

Collegium’s total revenue rose 31.4% to $209.36 million in Q3 2025, driven by robust sales across its product portfolio. The pain management segment generated $167.6 million in net revenue, while Jornay PM prescriptions grew 20% year-over-year.

Earnings/Net Income

The company’s EPS surged 244.8% to $1.00, with net income jumping 237.5% to $31.51 million. This marks a significant acceleration in profitability, supported by operational efficiencies and commercial execution. The earnings growth far outpaced market expectations, underscoring strong financial health.

Post-Earnings Price Action Review

Following the earnings release, Collegium’s stock gained 1.57% in a single trading day, reflecting immediate market approval. The rally accelerated to 14.05% for the week and 21.77% month-to-date, indicating sustained momentum. Analysts attributed the surge to improved guidance, strong revenue growth, and the company’s strategic focus on capital deployment and debt reduction. The stock’s performance aligns with broader investor optimism about Collegium’s ability to sustain momentum into 2026.

CEO Commentary

CEO Vikram Karnani highlighted the company’s success in driving Jornay PM growth during the back-to-school season and emphasized its commitment to commercial execution, business development, and disciplined capital use. He expressed confidence in the pipeline and long-term growth potential.

Guidance

Collegium raised 2025 full-year net revenue guidance to $775–$785 million (from $745–$760 million) and Adjusted EBITDA to $460–$470 million (from $440–$455 million). The company also announced $25 million in share repurchases under its $150 million buyback program, signaling confidence in its capital structure.

Additional News

1. Share Repurchase Program: Collegium completed a $25 million accelerated share repurchase in July 2025 and expanded its buyback authorization to $150 million through December 2026.

2. Acquisition of Ironshore Therapeutics: The 2024 acquisition of Ironshore, which added Jornay PM to Collegium’s portfolio, has driven entry into the ADHD market, with Jornay PM revenue expected to reach $145–$150 million in 2025.

3. Strategic Capital Deployment: The company prioritized debt reduction and shareholder returns, with CFO confirming alignment with guidance and a “solid foundation for 2026 growth.”

**

**

Collegium’s Q3 results highlight its ability to leverage a diversified product portfolio and strategic acquisitions to drive revenue and profitability. The company’s focus on capital efficiency and market expansion positions it to capitalize on long-term opportunities in pain management and neuropsychiatry.